hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06389188, orgStudyIdInfo id: JVT003, briefTitle: Effectiveness of Cervical Osteopathic Manipulation in Patients With Whiplash, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Universidad Miguel Hernandez de Elche, class: OTHER, collaborators name: Consorci Sanitari de Terrassa, descriptionModule briefSummary: To determine the mid- and long-term efficiency (15, 30 and 120 days after starting sessions) of the SAT technique in patients with grade II acute WL, comparing it with a conventional rehabilitation program., conditionsModule conditions: Whiplash, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: RHB Group, outcomesModule primaryOutcomes measure: Subjective pain intensity, primaryOutcomes measure: Neck specific disability, secondaryOutcomes measure: Cervical range of motion (CROM), secondaryOutcomes measure: Cervical lordosis Cobb angle, secondaryOutcomes measure: Hospital anxiety and depression scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Consorci Sanitari de Terrassa., city: Terrassa, state: Barcelona, zip: 08227, country: Spain, contacts name: Joan Parera-Turull, PhD, role: CONTACT, phone: 937310007, phoneExt: 0007, email: joanparera@osteopatiaterrassa.com, geoPoint lat: 41.56667, lon: 2.01667, hasResults: False
protocolSection identificationModule nctId: NCT06389162, orgStudyIdInfo id: UNLV-2024-115, briefTitle: Dorsolateral Prefrontal Cortex Transcranial Direct Current and Muscle Fatigue Stimulation on Muscle Fatigue, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University of Nevada, Las Vegas, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn if transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) can impact muscle fatigue. The main questions it aims to answer are:1. Does tDCS of the left DLPFC increase the time that a fatiguing contraction can be maintained?2. Does tDCS of the left DLPFC decrease the rate of increase of muscle activity, force error, and standard deviation of force during a fatiguing contraction.Researchers will compare tDCS of the left DLPFC to a SHAM stimulation (a type of stimulation that feels like real tDCS but does not elicit physiological effects) to see if tDCS of the left DLPFC works to reduce the progression of muscle fatigue.Participants will:Performing two experimental sessions held 3-10 days apart (usually 7 days) Perform a 9 hole pegboard test, maximum voluntary contractions, and a fatiguing contraction., conditionsModule conditions: Fatigue, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Double-blind, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: transcranial direct current stimulation, outcomesModule primaryOutcomes measure: Time to Task Failure, primaryOutcomes measure: Fatigue Index, secondaryOutcomes measure: Average EMG activity, secondaryOutcomes measure: Force error, secondaryOutcomes measure: Standard deviation of force, secondaryOutcomes measure: 9 Hole Pegboard Test, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Nevada Las Vegas, city: Las Vegas, state: Nevada, zip: 89154, country: United States, geoPoint lat: 36.17497, lon: -115.13722, hasResults: False
protocolSection identificationModule nctId: NCT06389123, orgStudyIdInfo id: 1788760, briefTitle: Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2028-03-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University of California, Davis, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer., conditionsModule conditions: Metastatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single treatment, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G., outcomesModule primaryOutcomes measure: [68Ga]Ga DOTA-5G PET/CT imaging, secondaryOutcomes measure: [177Lu]Lu DOTA-ABM-5G treatment, secondaryOutcomes measure: [177Lu]Lu DOTA-ABM-5G treatment efficacy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The University of California Davis Comprehensive Cancer Center, status: RECRUITING, city: Sacramento, state: California, zip: 95817, country: United States, contacts name: Julie L Sutcliffe, PhD, role: CONTACT, phone: 916-734-5536, email: jlsutcliffe@ucdavis.edu, geoPoint lat: 38.58157, lon: -121.4944, hasResults: False
protocolSection identificationModule nctId: NCT06389110, orgStudyIdInfo id: SOPH201-1023/III, briefTitle: Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12-30, primaryCompletionDateStruct date: 2027-06-30, completionDateStruct date: 2027-06-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Laboratorios Sophia S.A de C.V., class: INDUSTRY, descriptionModule briefSummary: Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in intraocular pressure, changes in the amplitude of accommodation, compared to placebo, as a treatment to delay the progression of myopia and axial ocular elongation in children., conditionsModule conditions: Myopia, conditions: Myopia, Progressive, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a study to demonstrate superiority, double-blind, randomized, controlled, comparative, and multicenter phase III clinical trial., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 123, type: ESTIMATED, armsInterventionsModule interventions name: Alleance®, interventions name: Placebo, outcomesModule primaryOutcomes measure: Changes in the spherical equivalent, primaryOutcomes measure: Changes in axial eye length, secondaryOutcomes measure: Incidence of unexpected adverse events related to the interventions, secondaryOutcomes measure: Incidence of photophobia between interventions, secondaryOutcomes measure: Changes in pupillary diameter between the interventions, secondaryOutcomes measure: Changes in Best Corrected Visual Acuity (BCVA), secondaryOutcomes measure: Changes in near best-corrected visual acuity, secondaryOutcomes measure: Changes in the amplitude of accommodation (AA) between interventions, secondaryOutcomes measure: Changes in intraocular pressure (IOP), eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06389097, orgStudyIdInfo id: J23152, secondaryIdInfos id: IRB00411454, type: OTHER, domain: JHM IRB, secondaryIdInfos id: P01CA272222, type: NIH, link: https://reporter.nih.gov/quickSearch/P01CA272222, briefTitle: SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization, acronym: (SEEtoTREAT), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-05, completionDateStruct date: 2029-05, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, class: OTHER, collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy., conditionsModule conditions: Prostate Cancer, conditions: Advanced Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Radium-223, interventions name: 177Lu-DOTATATE, interventions name: 177Lu-PSMA-617, outcomesModule primaryOutcomes measure: Mean absorbed dose to normal organs compared using different quantitative methods, secondaryOutcomes measure: Variability of intra-patient and inter-patient mean absorbed dose to normal organs compared using SPECT images, secondaryOutcomes measure: Mean absorbed dose to normal organs correlated with toxicity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06389084, orgStudyIdInfo id: 179939, briefTitle: Parents Together: Supporting Parents to Promote Healthy Behaviours in Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: The Hospital for Sick Children, class: OTHER, descriptionModule briefSummary: The Parents Together trial aims to determine if the Parents Together program consisting of virtual parent group sessions and coaching calls, will result in better health outcomes for children. The program which is facilitated by a Public Health Nurse seeks to encourage healthy lifestyle behaviours, help build strong family relationships, and promote child development and mental health., conditionsModule conditions: Child Eating Behaviours, conditions: Child Nutrition, conditions: Early Child Development, conditions: Parenting, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized control trial, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 128, type: ESTIMATED, armsInterventionsModule interventions name: Parents Together parenting course, outcomesModule primaryOutcomes measure: Child eating behaviours, secondaryOutcomes measure: Dietary intake and food environment, secondaryOutcomes measure: Nutritional risk, secondaryOutcomes measure: Physical Activity, Sedentary Time, Sleep Duration, secondaryOutcomes measure: Physical activity, secondaryOutcomes measure: Social and emotional development, secondaryOutcomes measure: Child development, secondaryOutcomes measure: Family psychosocial health, secondaryOutcomes measure: Parenting, secondaryOutcomes measure: Parenting sense of competence, secondaryOutcomes measure: sociodemographic, maternal and child characteristics, secondaryOutcomes measure: zBMI, secondaryOutcomes measure: Waist circumference, secondaryOutcomes measure: Blood pressure, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule locations facility: The Hospital for Sick Children, city: Toronto, state: Ontario, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06389071, orgStudyIdInfo id: PLS001, briefTitle: Laser Treatment for Lichen Sclerosus, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12-20, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Sciton, class: INDUSTRY, descriptionModule briefSummary: Fractional ablative laser treatment for Lichen Sclerosus lesion, conditionsModule conditions: Lichen Sclerosus Lesion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Fractional 2940 nm Laser, outcomesModule primaryOutcomes measure: Histological clearance, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinique Medicale Uro-Gyneco de l'Abitibi, status: RECRUITING, city: Val-d'Or, state: Quebec, zip: J9P1W1, country: Canada, contacts name: Josee Parent, MD, role: CONTACT, phone: 819-825-3800, geoPoint lat: 48.0974, lon: -77.79737, hasResults: False
protocolSection identificationModule nctId: NCT06389058, orgStudyIdInfo id: G00014538, briefTitle: Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2026-11, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: San Diego State University, class: OTHER, collaborators name: GlaxoSmithKline, collaborators name: Scripps Health, collaborators name: Modena Allergy + Asthma, La Jolla, CA, collaborators name: University of California, San Diego, descriptionModule briefSummary: The study aims to to use new technologies (ML, AI, NLP), to autonomously identify moderate to severe asthma populations within an EHR system, describe differences in treatment patterns across different populations, and determine trial eligibility.Primary Objectives Please ensure you detail primary objectives Aim 1. Determine and validate a diagnosis of severe asthma (SA) using predictive features obtained from the Scripps Health EHR.* Aim 1a: Use ML applied to structured EHR data to predict SA. Use the opinion of 2 specialty-trained physicians and ATS guidelines to determine model accuracy.* Aim 1b: Use NLP applied to unstructured text to predict SA. Determine model accuracy as above in Aim 1a.* Aim 1c: Use a combination of ML applied to structured data to predict SA. Determine model accuracy as above in Aim 1a., conditionsModule conditions: Severe Asthma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 31795, type: ACTUAL, armsInterventionsModule interventions name: Recommendation for the diagnoses and treatment of Severe Athma, outcomesModule primaryOutcomes measure: Identification of Patients with Severe Asthma, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 85 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: San Diego State University, city: San Diego, state: California, zip: 92182-1309, country: United States, geoPoint lat: 32.71533, lon: -117.15726, hasResults: False
protocolSection identificationModule nctId: NCT06389045, orgStudyIdInfo id: EUS, briefTitle: Profopol and Remifentanil Sedation in Endoscopic Ultrasonography, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-24, primaryCompletionDateStruct date: 2024-06-24, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Samsun University, class: OTHER, descriptionModule briefSummary: Endoscopic ultrasonography (EUS) is an endoscopic procedure performed to investigate conditions affecting the stomach, liver, and bile ducts, as well as for therapeutic interventions. The complexity of EUS can vary significantly, with increased complexity affecting procedure duration, technical success, and the occurrence of adverse events. For the comfort of patients and the success of the procedure, these interventions are typically performed under anesthesia with procedural sedation. To enhance the success rate of the procedure, reduce the risk of side effects, and maximize patient comfort, EUS is generally performed under sedation according to the recommendations of the American Society of Anesthesiologists (ASA). During sedation, the aim is for the patient to be more relaxed and comfortable while maintaining spontaneous respiratory function. Preserving spontaneous respiratory parameters is crucial for procedural safety., conditionsModule conditions: Sedation Complication, conditions: Endoscopic Ultrasonography, conditions: Procedural Sedation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Procedural Sedation, outcomesModule primaryOutcomes measure: Anesthesia related major complications, secondaryOutcomes measure: The prevalence of symptoms of inadequate sedation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Samsun University Faculty of Medicine, status: RECRUITING, city: Samsun, country: Turkey, contacts name: Caner Genc, M.D., role: CONTACT, phone: 5444846865, phoneExt: +90, email: dr.canergenc@gmail.com, geoPoint lat: 41.27976, lon: 36.3361, hasResults: False
protocolSection identificationModule nctId: NCT06389019, orgStudyIdInfo id: BLCA_CMUFH, secondaryIdInfos id: K2024-187-01, type: OTHER, domain: The First Affiliated Hospital of Chongqing Medical University, briefTitle: Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Mingzhao Xiao, class: OTHER, descriptionModule briefSummary: Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA., conditionsModule conditions: Bladder Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Deep learning system for prognostication prediction in bladder cancer, outcomesModule primaryOutcomes measure: Overall survival, secondaryOutcomes measure: Recurrence free survival, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400016, country: China, contacts name: QuanHao He, PHD, role: CONTACT, phone: 800-555-5555, email: 2020120460@stu.cqmu.edu.cn, contacts name: Mingzhao Xiao, PHD, role: CONTACT, phone: 023-89012557, email: 2023140134@stu.cqmu.edu.cn, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06389006, orgStudyIdInfo id: RC48-C025, briefTitle: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: RemeGen Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer, conditionsModule conditions: HR-positive, HER2-low Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 79, type: ESTIMATED, armsInterventionsModule interventions name: Disitamab Vedotin for Injection, interventions name: Toripalimab, interventions name: Epirubicin, interventions name: Cyclophosphamide, outcomesModule primaryOutcomes measure: Total pathological complete response (tpCR) rate, secondaryOutcomes measure: Breast pathological complete response（bpCR）, secondaryOutcomes measure: Event free survival (EFS), secondaryOutcomes measure: Disease-free survival (DFS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Adverse events (AEs), secondaryOutcomes measure: Change in cluster of differentiation 8 (CD8), secondaryOutcomes measure: Health-related quality of life - EORTC-QLQ-C30, secondaryOutcomes measure: Residual cancer burden score, secondaryOutcomes measure: Change in tumor-infiltrating lymphocytes (TILs), secondaryOutcomes measure: Change in programmed cell death protein L1 (PD-L1), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jiong Wu, city: Shanghai, state: Fudan University Shanghai Cancer Center, zip: 200032, country: China, contacts name: Jiong Wu, Ph.D, role: CONTACT, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False